Logo image of INKT

MINK THERAPEUTICS INC (INKT) Stock Fundamental Analysis

USA - NASDAQ:INKT - US6036932019 - Common Stock

13.23 USD
-0.43 (-3.15%)
Last: 11/7/2025, 8:00:02 PM
13.05 USD
-0.18 (-1.36%)
After Hours: 11/7/2025, 8:00:02 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to INKT. INKT was compared to 531 industry peers in the Biotechnology industry. INKT has a bad profitability rating. Also its financial health evaluation is rather negative. INKT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INKT had negative earnings in the past year.
In the past year INKT has reported a negative cash flow from operations.
INKT had negative earnings in each of the past 5 years.
INKT had a negative operating cash flow in each of the past 5 years.
INKT Yearly Net Income VS EBIT VS OCF VS FCFINKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

INKT has a worse Return On Assets (-453.80%) than 95.71% of its industry peers.
Industry RankSector Rank
ROA -453.8%
ROE N/A
ROIC N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INKT Yearly ROA, ROE, ROICINKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

INKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INKT Yearly Profit, Operating, Gross MarginsINKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, INKT has more shares outstanding
INKT has more shares outstanding than it did 5 years ago.
INKT has a worse debt/assets ratio than last year.
INKT Yearly Shares OutstandingINKT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M
INKT Yearly Total Debt VS Total AssetsINKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -104.08, we must say that INKT is in the distress zone and has some risk of bankruptcy.
INKT has a Altman-Z score of -104.08. This is amonst the worse of the industry: INKT underperforms 96.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -104.08
ROIC/WACCN/A
WACCN/A
INKT Yearly LT Debt VS Equity VS FCFINKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

INKT has a Current Ratio of 0.15. This is a bad value and indicates that INKT is not financially healthy enough and could expect problems in meeting its short term obligations.
INKT's Current ratio of 0.15 is on the low side compared to the rest of the industry. INKT is outperformed by 96.08% of its industry peers.
A Quick Ratio of 0.15 indicates that INKT may have some problems paying its short term obligations.
INKT's Quick ratio of 0.15 is on the low side compared to the rest of the industry. INKT is outperformed by 95.90% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
INKT Yearly Current Assets VS Current LiabilitesINKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

INKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.22%, which is quite impressive.
EPS 1Y (TTM)41.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INKT will show a small growth in Earnings Per Share. The EPS will grow by 6.38% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.59%
EPS Next 2Y20.98%
EPS Next 3Y12.15%
EPS Next 5Y6.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INKT Yearly Revenue VS EstimatesINKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2028 2029 2030 20M 40M 60M 80M
INKT Yearly EPS VS EstimatesINKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INKT Price Earnings VS Forward Price EarningsINKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INKT Per share dataINKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as INKT's earnings are expected to grow with 12.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.98%
EPS Next 3Y12.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INKT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINK THERAPEUTICS INC

NASDAQ:INKT (11/7/2025, 8:00:02 PM)

After market: 13.05 -0.18 (-1.36%)

13.23

-0.43 (-3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners1.37%
Inst Owner Change15.5%
Ins Owners7.66%
Ins Owner Change0.15%
Market Cap59.80M
Revenue(TTM)N/A
Net Income(TTM)-11.27M
Analysts82.5
Price Target39.78 (200.68%)
Short Float %3.53%
Short Ratio1.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.3%
Min EPS beat(2)-90.1%
Max EPS beat(2)-12.5%
EPS beat(4)1
Avg EPS beat(4)-21.36%
Min EPS beat(4)-90.1%
Max EPS beat(4)38.73%
EPS beat(8)4
Avg EPS beat(8)-0.91%
EPS beat(12)7
Avg EPS beat(12)3.81%
EPS beat(16)9
Avg EPS beat(16)-3.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-59.32%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.88
EYN/A
EPS(NY)-3.54
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS-5.57
TBVpS-5.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -453.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -104.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)185.6%
Cap/Depr(5y)359.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.43%
EPS Next Y43.59%
EPS Next 2Y20.98%
EPS Next 3Y12.15%
EPS Next 5Y6.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.56%
OCF growth 3YN/A
OCF growth 5YN/A

MINK THERAPEUTICS INC / INKT FAQ

Can you provide the ChartMill fundamental rating for MINK THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to INKT.


Can you provide the valuation status for MINK THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MINK THERAPEUTICS INC (INKT). This can be considered as Overvalued.


Can you provide the profitability details for MINK THERAPEUTICS INC?

MINK THERAPEUTICS INC (INKT) has a profitability rating of 0 / 10.